Literature DB >> 21900874

Respiratory syncytial virus--United States, July 2007-June 2011.

.   

Abstract

Each year in the United States, an estimated 75,000-125,000 hospitalizations related to respiratory syncytial virus (RSV)occur among children aged <1 year, and RSV infection results in approximately 1.5 million outpatient visits among children aged <5 years. In the United States, RSV season begins in the fall, peaks in winter, and ends in the late winter and early spring. However, the exact timing and duration vary from year to year and by geographic region. To describe trends in RSV seasonality, data from the National Respiratory and Enteric Virus Surveillance System (NREVSS) were used to determine the onset, offset, and peak of the July 2010--June 2011 RSV season, and for an aggregate analysis of the four most recent RSV seasons (July 2007--June 2011). During 2010--11, excluding Florida, season onset occurred from mid-November to early January, and offset occurred from mid-March to late April across all 10 U.S. Department of Health and Human Services (HHS) regions. Florida is reported separately because it has an earlier onset and longer duration than the rest of the country. During the four seasons from 2007 through 2011, onset among the HHS regions excluding Florida ranged from mid-October to early January, and offset ranged from early February to early May. Information on national and regional patterns can be used by clinicians and public health officials to guide diagnostic testing during respiratory disease outbreaks and determine when to provide RSV immunoprophylaxis for children at high risk for serious complications.

Entities:  

Mesh:

Year:  2011        PMID: 21900874

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  15 in total

1.  Effect of young sibling visitation on respiratory syncytial virus activity in a NICU.

Authors:  A M Peluso; B A Harnish; N S Miller; E R Cooper; A M Fujii
Journal:  J Perinatol       Date:  2015-04-02       Impact factor: 2.521

2.  Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-Optimal Protection Against Respiratory Syncytial Virus.

Authors:  Daniel M Weinberger; Joshua L Warren; Claudia A Steiner; Vivek Charu; Cécile Viboud; Virginia E Pitzer
Journal:  Clin Infect Dis       Date:  2015-04-22       Impact factor: 9.079

3.  Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.

Authors:  Gabriel J Robbie; Liang Zhao; John Mondick; Genevieve Losonsky; Lorin K Roskos
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

4.  Adherence to Immunoprophylaxis Regimens for Respiratory Syncytial Virus Infection in Insured and Medicaid Populations.

Authors:  Gabriel J Escobar; Tebeb Gebretsadik; Kecia Carroll; Sherian Xu Li; Eileen M Walsh; Pingsheng Wu; Ed Mitchel; Chantel Sloan; Tina Hartert
Journal:  J Pediatric Infect Dis Soc       Date:  2013-03-21       Impact factor: 3.164

5.  Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.

Authors:  Alexander Gutfraind; Alison P Galvani; Lauren Ancel Meyers
Journal:  JAMA Pediatr       Date:  2015-04       Impact factor: 16.193

6.  Determining the Seasonality of Respiratory Syncytial Virus in the United States: The Impact of Increased Molecular Testing.

Authors:  Claire M Midgley; Amber K Haynes; Jason L Baumgardner; Christina Chommanard; Sara W Demas; Mila M Prill; Glen R Abedi; Aaron T Curns; John T Watson; Susan I Gerber
Journal:  J Infect Dis       Date:  2017-08-01       Impact factor: 5.226

7.  Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996-2013.

Authors:  Ben Artin; Virginia E Pitzer; Daniel M Weinberger
Journal:  Sci Rep       Date:  2021-05-21       Impact factor: 4.996

8.  Respiratory syncytial virus surveillance in the United States, 2007-2012: results from a national surveillance system.

Authors:  Catherine Balderston McGuiness; Marnie L Boron; Brett Saunders; Laurel Edelman; Veena R Kumar; Karma M Rabon-Stith
Journal:  Pediatr Infect Dis J       Date:  2014-06       Impact factor: 2.129

9.  Respiratory syncytial virus epidemic periods in an equatorial city of Brazil.

Authors:  Fernanda E A Moura; Anne C B Perdigão; Joyce F Ribeiro; Caroline M G D Florêncio; Francisco M S Oliveira; Samuel A R Pereira; Viviane F Botosso; Marilda M Siqueira; Luciano M Thomazelli; Raquel N Caldeira; Danielle B L Oliveira; Edison L Durigon
Journal:  Influenza Other Respir Viruses       Date:  2013-03-20       Impact factor: 4.380

10.  Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.

Authors:  Christopher S Ambrose; Evan J Anderson; Eric A F Simões; Xionghua Wu; Hanaa Elhefni; C Lucy Park; Frangiscos Sifakis; Jessie R Groothuis
Journal:  Pediatr Infect Dis J       Date:  2014-06       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.